Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. InSilico Medicine Cayman TopCo's annualizedNet Income for the quarter that ended in Dec. 2025 was €-568.94 Mil.
InSilico Medicine Cayman TopCo's average Total Assets over the quarter that ended in Dec. 2025 was €313.83 Mil. Therefore, InSilico Medicine Cayman TopCo's annualized ROA % for the quarter that ended in Dec. 2025 was -181.29%.
The historical rank and industry rank for InSilico Medicine Cayman TopCo's ROA % or its related term are showing as below:
FRA:O15'
s ROA % Range Over the Past 10 Years
Min: -120.54 Med: -95.69 Max: -9.83
Current: -120.54
During the past 4 years, InSilico Medicine Cayman TopCo's highest ROA % was -9.83%. The lowest was -120.54%. And the median was -95.69%.
FRA:O15's ROA % is ranked worse than 95.31% of 2897
companies
in the Software industry
Industry Median: 1.76
vs FRA:O15: -120.54
InSilico Medicine Cayman TopCo (FRA:O15) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
InSilico Medicine Cayman TopCo ROA % Related Terms
InSilico Medicine Cayman TopCo ROA % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Software - Infrastructure subindustry, InSilico Medicine Cayman TopCo's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InSilico Medicine Cayman TopCo ROA % vs Software Industry
For the Software industry and Technology sector, InSilico Medicine Cayman TopCo's ROA % distribution charts can be found below:
* The bar in red indicates where InSilico Medicine Cayman TopCo's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
InSilico Medicine Cayman TopCo (FRA:O15) has a ROA % of -181.29% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on InSilico Medicine Cayman TopCo and its competitors. According to the industry distribution chart, InSilico Medicine Cayman TopCo ranks #2761 out of 2897 companies in the Software industry, placing it in the top 95.3%.
Is InSilico Medicine Cayman TopCo's ROA % too high?
InSilico Medicine Cayman TopCo's current ROA % is -181.29%. Based on the distribution chart, InSilico Medicine Cayman TopCo ranks #2761 out of 2897 companies in the Software industry, which is in the bottom quartile relative to peers. Overall, InSilico Medicine Cayman TopCo has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does InSilico Medicine Cayman TopCo's ROA % compare to MSFT and ORCL?
According to the Software industry distribution chart, InSilico Medicine Cayman TopCo ranks #2761 out of 2897 companies for ROA %. This places InSilico Medicine Cayman TopCo in the lower half of its industry. The industry median ROA % is 1.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Software company?
The median ROA % among Software companies is 1.76, based on 2,897 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on InSilico Medicine Cayman TopCo and its competitors. For the Software industry, the median ROA % is 1.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InSilico Medicine Cayman TopCo's current ROA % is -181.29%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InSilico Medicine Cayman TopCo stock overvalued right now?
InSilico Medicine Cayman TopCo (FRA:O15) has a current ROA % of -181.29%. The current ROA % is -181.29%. InSilico Medicine Cayman TopCo's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For InSilico Medicine Cayman TopCo (FRA:O15), the current ROA % is -181.29% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. It has generated multiple clinical-stage or IND-enabling assets using Pharma.AI, an AI-enabled platform that supports drug discovery and development activities. The company operates under a project-based business model, deriving revenue from out-licensing and collaboration arrangements. Geographically, the company generates revenue from multiple countries, with the majority of the revenue coming from United States.
20GF Score
Get the complete analysis for FRA:O15
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:O15 has been successfully added to your 
